CN108603231B - 检测癌症复发的方法 - Google Patents

检测癌症复发的方法 Download PDF

Info

Publication number
CN108603231B
CN108603231B CN201680062714.2A CN201680062714A CN108603231B CN 108603231 B CN108603231 B CN 108603231B CN 201680062714 A CN201680062714 A CN 201680062714A CN 108603231 B CN108603231 B CN 108603231B
Authority
CN
China
Prior art keywords
mutation
nucleic acid
motif
acid molecule
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680062714.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN108603231A (zh
Inventor
罗宾·林德利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gmdx Co Pty Ltd
Original Assignee
Gmdx Co Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903456A external-priority patent/AU2015903456A0/en
Application filed by Gmdx Co Pty Ltd filed Critical Gmdx Co Pty Ltd
Priority to CN202310693406.1A priority Critical patent/CN116574809A/zh
Publication of CN108603231A publication Critical patent/CN108603231A/zh
Application granted granted Critical
Publication of CN108603231B publication Critical patent/CN108603231B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680062714.2A 2015-08-26 2016-08-26 检测癌症复发的方法 Active CN108603231B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310693406.1A CN116574809A (zh) 2015-08-26 2016-08-26 检测癌症复发的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903456 2015-08-26
AU2015903456A AU2015903456A0 (en) 2015-08-26 Methods of detecting cancer recurrence
PCT/AU2016/050799 WO2017031551A1 (en) 2015-08-26 2016-08-26 Methods of detecting cancer recurrence

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310693406.1A Division CN116574809A (zh) 2015-08-26 2016-08-26 检测癌症复发的方法

Publications (2)

Publication Number Publication Date
CN108603231A CN108603231A (zh) 2018-09-28
CN108603231B true CN108603231B (zh) 2023-06-30

Family

ID=58099416

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680062714.2A Active CN108603231B (zh) 2015-08-26 2016-08-26 检测癌症复发的方法
CN202310693406.1A Withdrawn CN116574809A (zh) 2015-08-26 2016-08-26 检测癌症复发的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310693406.1A Withdrawn CN116574809A (zh) 2015-08-26 2016-08-26 检测癌症复发的方法

Country Status (7)

Country Link
US (1) US11225690B2 (enExample)
EP (1) EP3341496B1 (enExample)
JP (1) JP6850294B2 (enExample)
CN (2) CN108603231B (enExample)
AU (1) AU2016310415B2 (enExample)
ES (1) ES2873841T3 (enExample)
WO (1) WO2017031551A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6850294B2 (ja) 2015-08-26 2021-03-31 ジーエムディーエックス カンパニー プロプライエタリー リミテッド 癌の再発を検出する方法
US11875877B2 (en) 2016-08-25 2024-01-16 Nantomics, Llc Immunotherapy markers and uses therefor
WO2019095017A1 (en) * 2017-11-17 2019-05-23 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
CN108796077B (zh) * 2018-05-30 2021-11-09 朱运峰 在cfDNA中检测胞嘧啶脱氨酶及相关分子基因修饰差异的引物对组及试剂盒
EP4158070A4 (en) * 2020-06-01 2025-05-07 GMDx Co Pty Ltd METHODS FOR PREDICTING CANCER PROGRESSION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066955A1 (en) * 2012-11-05 2014-05-08 Lindley Robyn Alice Methods for determining the cause of somatic mutagenesis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
JP6850294B2 (ja) 2015-08-26 2021-03-31 ジーエムディーエックス カンパニー プロプライエタリー リミテッド 癌の再発を検出する方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014066955A1 (en) * 2012-11-05 2014-05-08 Lindley Robyn Alice Methods for determining the cause of somatic mutagenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Somatic mutation patterns in non-lymphoid cancers resemble the strand biased somatic hypermutation spectra of antibody genes;Edward J Steele, Robyn A Lindley，等;《DNA Repair》;20100601;第9卷(第6期);参见对比文件2第601页右栏第1段和第3段，表1 *

Also Published As

Publication number Publication date
JP2018531620A (ja) 2018-11-01
US11225690B2 (en) 2022-01-18
WO2017031551A1 (en) 2017-03-02
CN108603231A (zh) 2018-09-28
ES2873841T3 (es) 2021-11-04
CN116574809A (zh) 2023-08-11
HK1260327A1 (en) 2019-12-20
EP3341496A4 (en) 2019-03-27
EP3341496A1 (en) 2018-07-04
US20200232038A1 (en) 2020-07-23
AU2016310415A1 (en) 2018-04-19
EP3341496B1 (en) 2021-02-24
JP6850294B2 (ja) 2021-03-31
AU2016310415B2 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
US20220267864A1 (en) Therapeutic, diagnostic, and prognostic methods for cancer
JP6700333B2 (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
EP2582847B1 (en) Methods and materials for assessing loss of heterozygosity
US9410206B2 (en) Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer
US20230138572A1 (en) Method for determining the likelihood that a subject has or will develop cancer
CN108603231B (zh) 检测癌症复发的方法
US10036070B2 (en) Methods and means for molecular classification of colorectal cancers
JP2006520197A (ja) チミジレートシンターゼ遺伝子座におけるヘテロ接合性の喪失に基づいて化学療法計画を決定する方法
EP2460891A1 (en) Prognostic marker for mamma carcinoma
HK1260327B (en) Methods of detecting cancer recurrence
KR102325356B1 (ko) 유사유전자를 이용한 신경교종의 악성도 진단용 조성물 및 이의 이용
HK40120571A (en) Methods and materials for assessing loss of heterozygosity
KR20240067002A (ko) 종양주변 정상조직을 이용한 대장암 예후 예측용 마커
Aboalela Acquired epigenetic and chromosomal changes in women treated for breast cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant